Minimal Residual Disease (MRD) testing helps detect tiny cancer cell populations that may remain after treatment. By identifying these cells before they can cause a recurrence, MRD testing enables early intervention and improves the chances of long-term remission.
Minimal Residual Disease (MRD) testing is a highly sensitive method that detects even the smallest number of cancer cells remaining in the body after treatment. These residual cells, often undetectable by conventional imaging or routine tests, can lead to relapse if not identified early. MRD testing provides a deeper insight into the body’s response to treatment by analyzing genetic material at a molecular level.
MRD testing at Neeli Genetics uses state-of-the-art molecular diagnostic techniques to detect minimal residual cancer cells with unmatched sensitivity. By examining the genetic material in blood or bone marrow samples, we can identify traces of cancer that are often missed by traditional imaging. This allows for more precise cancer monitoring and a better understanding of how a patient is responding to treatment.
MRD testing plays a vital role in cancer management, especially in hematologic malignancies like leukemia and lymphoma. It helps clinicians make informed decisions about ongoing treatment, monitor remission, and act quickly if cancer starts to return. Early detection through MRD can directly influence survival rates and patient outcomes.
MRD testing is a critical tool in personalized cancer care, enabling early detection of residual disease and reducing the chances of cancer relapse. At Neeli Genetics, MRD results guide doctors in making informed decisions about treatment adjustments, ensuring that therapies are tailored to the patient’s unique condition. This proactive approach supports long-term remission, improves survival rates, and empowers better outcomes for patients undergoing cancer treatment.
Early Detection: MRD testing can detect small amounts of cancer cells before they lead to recurrence.
Proactive Treatment: Identifying remaining cancer cells early enables the initiation of targeted treatments to prevent relapse.
High Sensitivity: The test is highly sensitive, identifying cancer at much lower levels than traditional imaging.
Schedule a consultation to discuss if MRD testing is right for you.
Meet with our RGCC cancer experts to understand the benefits of MRD testing and how it can impact your cancer management.
A blood sample is drawn and sent to RGCC’s certified lab for processing and cellular activation.
Receive precise results that help guide your treatment decisions.
MRD testing is a highly sensitive diagnostic tool that detects small numbers of cancer cells that may remain in the body after treatment. These cells are often undetectable through conventional scans, but they can lead to relapse if not addressed early.
MRD testing is especially recommended for patients diagnosed with blood cancers such as leukaemia, lymphoma, and multiple myeloma, particularly after completing treatment. It is also useful during remission to monitor for any signs of recurrence.
The test requires a blood or bone marrow sample (typically 5–10 ml), which is analysed using advanced molecular techniques to identify residual cancer cells at extremely low levels.
Results are typically available within 7 to 14 days, depending on the complexity of the analysis and sample type. These results help your medical team make timely and informed decisions about further treatment or surveillance.
Even when imaging tests show no signs of cancer, a few undetectable cells can remain. MRD testing allows for early detection and proactive intervention, helping to prevent relapse and improve long-term outcomes.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.